Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 131

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 131
---
-Funded Warrants are exercised, and after deducting Placement Agent fees and estimated offering expenses payable by us. 72 The dilution information above is for illustration purposes only. Our as adjusted net tangible book value following the closing of this offering will depend on the actual public offering price and other terms of this offering determined at pricing. The number of shares of Common Stock that will be outstanding after this offering is based on 1,475,426 shares of Common Stock outstanding as of September 30, 2024 (giving retroactive effect to the Reverse Stock Split), and excludes:

| ● | 26,575                                                 
 shares of Common Stock underlying outstanding options; |

| ● | 45,151                                                                                       
 shares of Common Stock issuable under our 2016 Plan and our 2024 Plan, which includes 45,141 
 shares of Common Stock reserved for issuance under our 2016 Plan and our 2024 Plan;          |

| ● | 5,272                                                                                        
 shares of Common Stock issuable under our 2024 ESPP, which includes 527,182 shares of Common 
 Stock reserved for issuance under our 2024 ESPP;                                             |

| ● | 95,175                                                                                     
 shares of Common Stock issuable upon the exercise of Public Warrants and Private Placement 
 Warrants;                                                                                  |

| ● | 87,879                                                                                       
 shares of Common Stock issuable upon the exercise of Common Warrants issued in the offerings 
 of our Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock; and  |

| ● | 1,345,679                                                                                 
 shares of Common Stock issuable upon conversion of the Series A Preferred Stock, Series B 
 Preferred Stock, and Series C Preferred Stock, including 497,977 shares issuable upon the 
 exercise of Preferred Warrants.                                                           |

To the extent any outstanding options are exercised, new options or other equity awards are issued under our equity incentive plans, or we issue additional equity or convertible securities in the future, there will be further dilution to new investors participating in this offering. 73 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION PBAX, and after the Business Combination, CERo, is providing the following unaudited pro forma condensed combined financial information to aid you in your analysis of the financial aspects of the Business Combination and related transactions. The following unaudited pro forma condensed financial information presents the combination of the financial information of PBAX and Legacy CERo